Plasma eMTBR-tau243 as a disease biomarker across Alzheimer's disease clinical phenotypes.

Authors

Jennifer L Whitwell, Jerusha G Bhaskaran, Ryota Satoh, Jonathan Graff-Radford, Mary M Machulda, Val J Lowe, Michelle M Mielke, Dennis W Dickson, Shin-Cheng Tzeng, John Bui, Philip B Verghese, Tim West, Venky Venkatesh, Keith A Josephs

Published in

Alzheimer's & dementia : the journal of the Alzheimer's Association. Volume 22. Issue 10. Pages e71898.

Abstract

The concentration of endogenous tau microtubule-binding region containing residue-243 in plasma (eMTBR-tau243) has been proposed to be a sensitive biomarker of tangle pathology in Alzheimer's disease (AD). We assessed eMTBR-tau243 and phosphorylated tau217 (p-tau217) with tau and Aβ-positron emission tomography (PET) across different AD clinical phenotypes.
Plasma eMTBR-tau243, p-tau217, and the ratio of non-phosphorylated to phosphorylated tau217 (%p-tau217) were measured in 20 Aβ-PET positive AD patients representing four clinical phenotypes and 10 cognitively unimpaired controls. Plasma levels were correlated with PET, demographic and cognitive variables.
Plasma eMTBR-tau243, p-tau217, and %p-tau217 levels were greater in AD than controls, with greatest levels observed in motor-predominant AD. Plasma biomarker levels correlated with cortical flortaucipir-PET uptake; eMTBR-tau243 correlations were strongest. In AD, eMTBR-tau243 levels were undetectable in patients with mild/focal flortaucipir-PET uptake (45%). Only eMTBR-tau243 correlated with cognition.
Plasma eMTBR-tau243 may be an excellent biomarker for tau deposition and cognition in AD across different phenotypes.

PMID:
42851168
Bibliographic data and abstract were imported from PubMed on 09 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.